AMPC is a TFF3 inhibitor with antitumor activity and inhibits tumor growth in vivo. AMPC inhibits cell proliferation and survival in TFF3-positive CMS4 colorectal cancer cells and can be used to study colorectal cancer.

SW480 cells:69.69 μM, SW620 cells:2.63 μM, Caco2 cells:4.65 μM

The IC50 values of AMPC in CMS4 CRC cells were determined. We observed that SW620 cells with high TFF3 expression were slightly more sensitive to AMPC than Caco2 cells with low TFF3 expression. SW620 IC50=2.63 μM; Caco2 IC50=4.65 μM; SW480 IC50=69.69 μM. [1]

SW620 cells were subcutaneously injected into nude mice. The mice were randomly divided into two groups (n = 8) and intraperitoneally injected daily with AMPC at a dose of 40 mg/kg body weight or equivalent amount of vehicle for two weeks. The average tumour weight of the AMPC -treated group was significantly less than that of the vehicle-treated group. AMPC treatment resulted in larger areas of tumour necrosis and increased area of cells with apoptotic features. AMPC treatment significantly reduced tumour and serum TFF3 levels. [1]